SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

FRE

39.42

-0.45%↓

PHIA

22.93

-2.43%↓

SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

FRE

39.42

-0.45%↓

PHIA

22.93

-2.43%↓

SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

FRE

39.42

-0.45%↓

PHIA

22.93

-2.43%↓

SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

FRE

39.42

-0.45%↓

PHIA

22.93

-2.43%↓

SAN

100.18

-2.09%↓

EI

267.6

-0.04%↓

SHL.DE

49.92

-0.72%↓

FRE

39.42

-0.45%↓

PHIA

22.93

-2.43%↓

Search

Argenx SE

Cerrado

SectorSalud

534.2 -1.62

Resumen

Variación precio

24h

Actual

Mínimo

523.8

Máximo

542.8

Métricas clave

By Trading Economics

Ingresos

690M

774M

Ventas

165M

738M

P/B

Media del Sector

46.107

63.778

BPA

0.72

Margen de beneficio

104.841

Empleados

1,599

EBITDA

126M

89M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

-2.07% downside

Dividendos

By Dow Jones

Próximas Ganancias

8 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-2.5B

34B

Apertura anterior

535.82

Cierre anterior

534.2

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

317 / 386 Clasificación en Healthcare

Argenx SE Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 abr 2025, 23:15 UTC

Principales Movimientos del Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1 abr 2025, 23:46 UTC

Charlas de Mercado

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1 abr 2025, 23:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 abr 2025, 23:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 abr 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1 abr 2025, 23:43 UTC

Charlas de Mercado

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1 abr 2025, 23:11 UTC

Principales Noticias

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

1 abr 2025, 23:02 UTC

Charlas de Mercado

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1 abr 2025, 22:31 UTC

Principales Noticias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 abr 2025, 22:26 UTC

Charlas de Mercado

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1 abr 2025, 21:47 UTC

Principales Noticias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 abr 2025, 21:32 UTC

Principales Noticias

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

1 abr 2025, 21:06 UTC

Charlas de Mercado

Mexican Remittances See Slow Start to the Year -- Market Talk

1 abr 2025, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

1 abr 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

1 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 abr 2025, 20:47 UTC

Principales Noticias

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

1 abr 2025, 20:47 UTC

Principales Noticias

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

1 abr 2025, 20:20 UTC

Principales Noticias

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1 abr 2025, 20:15 UTC

Adquisiciones, fusiones, absorciones

Eaton Completes Acquisition Of Fibrebond >ETN

1 abr 2025, 20:11 UTC

Charlas de Mercado

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1 abr 2025, 20:07 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 abr 2025, 20:00 UTC

Principales Noticias

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

1 abr 2025, 19:46 UTC

Principales Noticias

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1 abr 2025, 19:43 UTC

Charlas de Mercado

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1 abr 2025, 19:17 UTC

Principales Noticias

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1 abr 2025, 19:13 UTC

Charlas de Mercado

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1 abr 2025, 19:03 UTC

Charlas de Mercado

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1 abr 2025, 19:00 UTC

Charlas de Mercado

Gold Slips Ahead of Tariff Day -- Market Talk

1 abr 2025, 18:54 UTC

Charlas de Mercado

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Comparación entre iguales

Cambio de precio

Argenx SE Esperado

Precio Objetivo

By TipRanks

-2.07% caída

Estimación a 12 meses

Media 438.33 EUR  -2.07%

Máximo 545 EUR

Mínimo 223 EUR

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Argenx SE Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

5

Comprar

0

Mantener

1

Vender

Sentimiento

By Acuity

317 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.